Neutropenia Pipeline Insights

DelveInsight’s “Neutropenia Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Neutropenia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Neutropenia Disease Understanding

Neutropenia Overview

Neutropenia is a hematological disorder characterized by an abnormally low absolute neutrophil count (ANC), typically defined as <1.5 × 10?/L, with severe neutropenia occurring at <0.5 × 10?/L. As neutrophils are the primary defense against bacterial and fungal pathogens, neutropenia markedly increases susceptibility to recurrent and life-threatening infections. The condition may be acute or chronic and can be congenital, acquired, or immune mediated. Common etiologies include chemotherapy, hematologic malignancies, autoimmune diseases, viral infections, nutritional deficiencies, medications, and inherited disorders affecting neutrophil production or survival.

The clinical manifestations of neutropenia depend on its severity and duration. Many patients remain asymptomatic until infections occur, while others present with recurrent fever, oral ulcers, gingivitis, skin and soft tissue infections, pneumonia, or sepsis. The underlying pathophysiology varies according to the cause and may involve impaired granulopoiesis within the bone marrow, accelerated peripheral destruction of neutrophils through immune-mediated mechanisms, abnormal neutrophil maturation, or defective mobilization from the marrow. Genetic mutations affecting neutrophil development, bone marrow suppression by cytotoxic agents, and dysregulated cytokine signaling are key mechanisms contributing to chronic and severe forms of neutropenia.

Diagnosis is based on repeated complete blood counts with differential to confirm persistent neutropenia, followed by evaluation of the patient's clinical history, medication exposure, nutritional status, infectious causes, autoimmune markers, and, when indicated, bone marrow examination and genetic testing. Additional investigations help distinguish congenital, autoimmune, and secondary causes.

Management depends on the underlying etiology and severity, with prompt initiation of broad-spectrum antibiotics for febrile neutropenia, discontinuation of causative medications, and treatment of underlying disorders. Granulocyte colony-stimulating factor (G-CSF), such as filgrastim or pegfilgrastim, remains the cornerstone of therapy for severe chronic and chemotherapy-induced neutropenia, while hematopoietic stem cell transplantation may be considered for selected patients with severe congenital neutropenia or bone marrow failure syndromes.

"Neutropenia Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Neutropenia pipeline landscape is provided which includes the disease overview and Neutropenia treatment guidelines. The assessment part of the report embraces, in depth Neutropenia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Neutropenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Neutropenia Pipeline Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Neutropenia R&D. The therapies under development are focused on novel approaches to treat/improve Neutropenia.

Neutropenia Emerging Drugs Chapters

This segment of the Neutropenia report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Neutropenia Emerging Drugs

Mavorixafor: X4 Pharmaceuticals

Mavorixafor is an investigational oral CXCR4 antagonist developed by X4 Pharmaceuticals for the treatment of chronic neutropenic disorders, including congenital, primary autoimmune, and idiopathic chronic neutropenia. By selectively blocking the CXCR4/CXCL12 signaling pathway, mavorixafor promotes the mobilization of mature neutrophils from the bone marrow into the peripheral circulation, thereby increasing absolute neutrophil counts and reducing the risk of recurrent infections. It is currently being evaluated in the global Phase III 4WARD trial, a randomized, double-blind, placebo-controlled study assessing its efficacy, safety, and tolerability in patients receiving standard background therapy with or without granulocyte colony-stimulating factor (G-CSF).

EMD-101: Emendo biotherapeutics

EMD-101 is an investigational ex vivo CRISPR-based gene-editing therapy being developed by EmendoBio for the treatment of severe congenital neutropenia (SCN) caused by dominant ELANE gene mutations. The therapy uses EmendoBio's proprietary allele-specific CRISPR nuclease to selectively excise the mutant ELANE allele in autologous hematopoietic stem and progenitor cells (HSPCs), with the goal of restoring normal neutrophil maturation while preserving the healthy allele. Designed as a potentially curative, one-time treatment, EMD-101 aims to overcome the limitations of lifelong granulocyte colony-stimulating factor (G-CSF) therapy and allogeneic stem cell transplantation. The program is currently in the IND-enabling stage, with preclinical studies demonstrating highly specific mutant allele editing and successful differentiation of edited HSPCs into functional neutrophils.

Further product details are provided in the report...

Neutropenia Therapeutic Assessment

This segment of the report provides insights about the different Neutropenia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Neutropenia

There are approx. 10+ key companies which are developing the therapies for Neutropenia. The companies which have their Neutropenia drug candidates in the most advanced stage, i.e. Phase III include, X4 Pharmaceuticals.

Neutropenia Clincial Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Neutropenia Drugs Route of Administration

Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Neutropenia Drugs Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Neutropenia Pipeline Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Neutropenia Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Neutropenia therapeutic drugs key players involved in developing key drugs.

Neutropenia Clinical Trials Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Neutropenia drugs.

Neutropenia Pipeline Report Insights

• Neutropenia Pipeline Analysis
• Neutropenia Therapeutic Assessment
• Neutropenia Unmet Needs
• Impact of Neutropenia Drugs

Neutropenia Pipeline Report Assessment

• Neutropenia Pipeline Product Profiles
• Neutropenia Therapeutic Assessment
• Neutropenia Pipeline Assessment
• Inactive Neutropenia drugs assessment
• Neutropenia Unmet Needs

Key Questions Answered In The Neutropenia Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Neutropenia drugs?
• How many Neutropenia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Neutropenia?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Neutropenia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Neutropenia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Neutropenia Companies

• X4 Pharmaceuticals
• Emendo biotherapeutics
• Bolder BioTechnology
• UBI Pharma
• Akthelia

Key Neutropenia Pipeline Products

• Mavorixafor
• EMD-101
• BBT 007
• UB-853
• AKt-011